Matisse Pharmaceuticals

Netherlands
Spankeren, Gelderland, The Netherlands, 6163 JT

Company profile

Matisse Pharmaceuticals company profile

Matisse Pharmaceuticals is a biotechnology company dedicated to development of pharmaceutical therapies to treat disorders that are associated with fulminant inflammation such as sepsis. The most advanced product in development is the heparin fraction M6229 for the treatment of severe sepsis and septic shock.

Business identity

Contact email
[email protected]
Phone number
+31 (0)88 2554 070
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Founded
2014-01-01, Year

Headquarters

Postal code
6163 JT
Country code
NL
Continent
Europe

Capital profile

Funding and company signals

Funding rounds
2
Total equity funding
$6M
Last funding
Series Unknown / $3.9M / 2024-01-04
Last equity funding
Series Unknown / $3.9M
Investors
3
Lead investors
2
Articles
5

Founders and investors

Lead investors

Brightlands Venture PartnersChemelot Ventures

Investors

Brightlands Venture PartnersChemelot VenturesLimburg Business Development Fund (LBDF)